Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan

RT @evideraglobal: Congratulations to @Hernandez_LuisG for co-authoring this interesting #publication that assessed the cost-effectiveness…

RT @Hernandez_LuisG: Our latest research on the cost effectiveness of biologics for ulcerative colities in Japan has just been published in…

Congratulations to @Hernandez_LuisG for co-authoring this interesting #publication that assessed the cost-effectiveness of vedolizumab versus other branded biologics for the treatment of patients in Japan with moderate-to-severe #ulcerativecolitis https://

Our latest research on the cost effectiveness of biologics for ulcerative colities in Japan has just been published in @PECjournal @Springernomics, presenting new and clear NMA and modeling approaches - @evideraglobal https://t.co/OD2l7G7MPs

#HealthEconJA Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan https://t.co/qiPvVtioUY